(487) The Effects of Cinacalcet on Parathyroid Adenoma Localization

Monday, October 2, 2023

2:45 PM – 3:45 PM East Coast USA Time

Presenting Author(s)

JT

James B. Tansey, MD

Resident
University of Tennessee
Memphis, TN, United States
Andrew J. Maroda, MD

Resident Physician
University of Tennessee Health Science Center
Memphis, Tennessee, United States

Co-Author(s)

JM

Jeffery A. May, II, MD

University of Tennessee Health Science Center, TN, USA
JL

Jordan B. Luttrell, MD

Resident
University of Tennessee
Memphis, TN, United States

Senior Author(s)

ES

Eugene R. Sansoni, MD

UTHSC Department of Otolaryngology Head-Neck Surgery, USA

Co-Author(s)

NB

Nicholas Bosworth, MD

University of Tennessee, TN, USA
AB

Abby Bennett, Other

University of Tennessee, USA

Disclosure(s):

Andrew J. Maroda, MD: No relevant relationships to disclose.

Introduction: To assess whether patients with primary hyperparathyroidism (PHPT) on or previously on Cinacalcet therapy have more equivocal parathyroid adenoma localization studies compared to patients who have never received Cinacalcet therapy.

Methods: Retrospective chart review was performed at Memphis VA Medical Center. All patients from 2013 to 2022 who underwent Sestamibi imaging to evaluate PHPT were included. All preoperative and postoperative lab values, imaging findings, operative findings and basic demographic data were collected. Patients were divided into Cinacalcet vs non-Cinacalcet groups and previously mentioned data points, particularly localizing versus non-localizing Sestamibi scans were directly compared.

Results: Of the 177 patients captured within the initial cohort, 142 patients met inclusion criteria. 68 subjects had previously been on Cinacalcet therapy. Of the 74 patients not on Cinacalcet, 49 (68%) were localizing on Sestamibi scan. Of the 68 patients previously treated with Cinacalcet, 30 (44.1%) localized (p < 0.05).

Conclusions: Patients who have previously been on Cinacalcet therapy are more likely to have non-localizing Sestamibi scans. Previous studies have suggested reduction in parathyroid adenoma size as well as decreased scintigraphy uptake of adenomas in patients with PHPT for patients on Cinacalcet therapy. Further research is required to determine if these patients would benefit from better first line imaging.